NASDAQ:SYRE 2 January 2026 - 5 January 2026

Spyre Therapeutics shares fell 2.7% to $29.75 Monday as biotech stocks underperformed, with the SPDR S&P Biotech ETF down 1.7% and the S&P 500 ETF up 0.7%. Investors are watching for 2026 clinical trial updates and the company’s late-February quarterly report.

Spyre Therapeutics (SYRE) fell 6.6% to $30.58 Friday, trading between $30.11 and $32.89 on about 889,000 shares. The company expects key Phase 2 trial data in ulcerative colitis and rheumatic diseases in 2026. Shares ticked up 2% after hours. Investors are watching for macroeconomic data and sector news as markets reopen Monday.